Literature DB >> 12663634

The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.

J Moppett1, G A A Burke, C G Steward, A Oakhill, N J Goulden.   

Abstract

Risk directed treatment forms a central component of modern protocols for childhood acute lymphoblastic leukaemia (ALL). A review of recent studies of minimal residual disease (MRD) analysis shows that it is a powerful prognostic factor in both first line and relapse treatment. However, the value of MRD analysis is both time point and protocol specific, and the threshold for MRD detection of the technique used impacts upon the results obtained. MRD analysis does have a useful role to play in the risk directed treatment of childhood ALL, and this is currently being investigated in large prospective studies.

Entities:  

Mesh:

Year:  2003        PMID: 12663634      PMCID: PMC1769921          DOI: 10.1136/jcp.56.4.249

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

1.  A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia.

Authors:  C Guidal; E Vilmer; B Grandchamp; H Cavé
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

2.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.

Authors:  E Coustan-Smith; J Sancho; M L Hancock; J M Boyett; F G Behm; S C Raimondi; J T Sandlund; G K Rivera; J E Rubnitz; R C Ribeiro; C H Pui; D Campana
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

3.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.

Authors:  E Coustan-Smith; F G Behm; J Sanchez; J M Boyett; M L Hancock; S C Raimondi; J E Rubnitz; G K Rivera; J T Sandlund; C H Pui; D Campana
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

4.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

Authors:  P S Gaynon; M E Trigg; N A Heerema; M G Sensel; H N Sather; G D Hammond; W A Bleyer
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

5.  Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

Authors:  O B Eden; G Harrison; S Richards; J S Lilleyman; C C Bailey; J M Chessells; I M Hann; F G Hill; B E Gibson
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

Review 6.  Childhood acute lymphoblastic leukaemia--current status and future perspectives.

Authors:  C H Pui; D Campana; W E Evans
Journal:  Lancet Oncol       Date:  2001-10       Impact factor: 41.316

7.  Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.

Authors:  M J Pongers-Willemse; T Seriu; F Stolz; E d'Aniello; P Gameiro; P Pisa; M Gonzalez; C R Bartram; E R Panzer-Grümayer; A Biondi; J F San Miguel; J J van Dongen
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

8.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

Authors:  Michael N Dworzak; Gertraud Fröschl; Dieter Printz; Georg Mann; Ulrike Pötschger; Nora Mühlegger; Gerhard Fritsch; Helmut Gadner
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

9.  Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

Authors:  P Bader; J Hancock; H Kreyenberg; N J Goulden; D Niethammer; A Oakhill; C G Steward; R Handgretinger; J F Beck; T Klingebiel
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

10.  A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia.

Authors:  C G Steward; N J Goulden; F Katz; D Baines; P G Martin; K Langlands; M N Potter; J M Chessells; A Oakhill
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

View more
  7 in total

1.  Minimal metastatic disease.

Authors:  M M Reid
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 2.  Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-03-08

3.  A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

Authors:  Anne L Angiolillo; Alice L Yu; Gregory Reaman; Ashish M Ingle; Rita Secola; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

4.  A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.

Authors:  Carlos A Scrideli; Juliana G Assumpção; Mônica A Ganazza; Marcela Araújo; Silvia R Toledo; Maria Lúcia M Lee; Elisabete Delbuono; Antonio S Petrilli; Rosane P Queiróz; Andrea Biondi; Marcos B Viana; José A Yunes; Silvia R Brandalise; Luiz G Tone
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

5.  Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.

Authors:  Manal Salah-Eldin; Nashwa Khairat Abousamra; Hanan Azzam
Journal:  Med Oncol       Date:  2014-04-02       Impact factor: 3.064

6.  SVSI: fast and powerful set-valued system identification approach to identifying rare variants in sequencing studies for ordered categorical traits.

Authors:  Wenjian Bi; Guolian Kang; Yanlong Zhao; Yuehua Cui; Song Yan; Yun Li; Cheng Cheng; Stanley B Pounds; Michael J Borowitz; Mary V Relling; Jun J Yang; Zhifa Liu; Ching-Hon Pui; Stephen P Hunger; Christine M Hartford; Wing Leung; Ji-Feng Zhang
Journal:  Ann Hum Genet       Date:  2015-05-11       Impact factor: 1.670

7.  Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Authors:  Nicola Gökbuget; Hervé Dombret; Sebastian Giebel; Monika Brüggemann; Michael Doubek; Robin Foa; Dieter Hoelzer; Christopher Kim; Giovanni Martinelli; Elena Parovichnikova; Josep Maria Ribera; Marieke Schoonen; Catherine Tuglus; Gerhard Zugmaier; Renato Bassan
Journal:  Eur J Haematol       Date:  2020-01-24       Impact factor: 2.997

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.